40 min
Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug The Readout Loud
-
- Business
We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's such a big deal, and then we'll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we'll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.
We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's such a big deal, and then we'll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we'll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.
40 min